A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway AlterationsYiqun Zhang, Chad J. Creighton, Patrick Kwok‐Shing Ng et al.|Cancer Cell|2017Cited by 656
Multilevel Genomics-Based Taxonomy of Renal Cell CarcinomaFengju Chen, Chad J. Creighton, Yiqun Zhang et al.|Cell Reports|2016Cited by 382
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Fabio A.B. Schutz et al.|Cancer Immunology Research|2018Cited by 136
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Toni K. Choueiri, Nieves Martínez Chanzá et al.|JAMA Oncology|2021Cited by 95
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.Zachary A. Yochum, Toni K. Choueiri, Renée Maria Saliby et al.|Journal of Clinical Oncology|2025Cited by 0